Physician profile
Greg Rosenn
NPI 1598707697
$33,917.88
in general payments reported to CMS, 2019-2025
23 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 76% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,070 · 2020: $1,543 · 2021: $12K · 2022: $6,690 · 2023: $2,981 · 2024: $1,702 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,862 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,861.83 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $16,627.01 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Supernus Pharmaceuticals, INC. | $9,017.65 | 2019-2025 | Qelbree, Qelbree |
| Neurelis, INC. | $1,243.35 | 2020-2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $1,188.92 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, Lp | $1,145.82 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Ucb, INC. | $916.58 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Corium, LLC | $901.96 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $690.72 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $432.61 | 2019-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $327.61 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $327.14 | 2022-2023 | |
| Greenwich Biosciences, INC. | $319.28 | 2019-2021 | |
| Adlon Therapeutics L.P. | $273.88 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $193.88 | 2019-2021 | |
| Cranial Technologies, INC | $68.19 | 2021-2025 | Doc Band |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $66.13 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $52.38 | 2019-2020 | |
| Cognoa, INC. | $30.51 | 2022 | |
| Shire North American Group INC | $21.05 | 2019 | |
| Avion Pharmaceuticals | $19.58 | 2024 | Relexxii |
| Amneal Pharmaceuticals LLC | $18.30 | 2019 | |
| Eisai INC. | $18.23 | 2021 | |
| Zogenix INC. | $17.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Rosenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.